Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Praxis Precision Medicines (PRAX) EBITDA (2022 - 2025)

Historic EBITDA for Praxis Precision Medicines (PRAX) over the last 4 years, with Q3 2025 value amounting to -$78.4 million.

  • Praxis Precision Medicines' EBITDA fell 3787.1% to -$78.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$293.1 million, marking a year-over-year decrease of 7870.93%. This contributed to the annual value of -$200.2 million for FY2024, which is 5839.22% down from last year.
  • Praxis Precision Medicines' EBITDA amounted to -$78.4 million in Q3 2025, which was down 3787.1% from -$76.1 million recorded in Q2 2025.
  • Praxis Precision Medicines' 5-year EBITDA high stood at -$25.5 million for Q3 2023, and its period low was -$78.4 million during Q3 2025.
  • Over the past 4 years, Praxis Precision Medicines' median EBITDA value was -$44.3 million (recorded in 2022), while the average stood at -$51.4 million.
  • As far as peak fluctuations go, Praxis Precision Medicines' EBITDA soared by 4467.46% in 2023, and later crashed by 13000.79% in 2024.
  • Quarter analysis of 4 years shows Praxis Precision Medicines' EBITDA stood at -$41.5 million in 2022, then skyrocketed by 32.92% to -$27.8 million in 2023, then tumbled by 130.01% to -$64.0 million in 2024, then fell by 22.52% to -$78.4 million in 2025.
  • Its EBITDA was -$78.4 million in Q3 2025, compared to -$76.1 million in Q2 2025 and -$74.7 million in Q1 2025.